CatenaBio has developed the CysTyr™ platform, which utilizes the Catenase™ enzyme to form proprietary C-Y Bonds™ between proteins using native amino acids, enabling the rapid and selective attachment of multiple therapeutic modalities. This technology addresses the limitations of current protein conjugation methods, facilitating the creation of novel therapeutics for autoimmune disorders, oncology, and vaccine development.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current protein conjugation methods face limitations in size, complexity, speed, stability, selectivity, and scalability, hindering the development of novel therapeutics. These constraints restrict the ability to attach multiple different cargoes to a protein, limiting the creation of multi-functional biologics. Existing approaches struggle to efficiently create complex protein structures with diverse therapeutic modalities.
Solution
CatenaBio's CysTyr™ platform leverages the Catenase™ enzyme to form proprietary C-Y Bonds™ between proteins using native amino acids, enabling rapid and selective attachment of multiple therapeutic modalities. This technology overcomes the limitations of current protein conjugation methods by eliminating size and complexity constraints. The CysTyr™ platform allows for the attachment of multiple different cargoes to a single protein, facilitating the creation of novel therapeutics with enhanced functionality. This approach offers improved speed, stability, selectivity, and scalability compared to existing conjugation techniques, enabling the development of more complex and effective biologic structures. The platform aims to simplify the process of building with biologics, making it as straightforward as working with small molecules.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions involved in developing novel therapeutics for autoimmune disorders, oncology, and vaccine development.
Features
- Catenase™ enzyme-mediated formation of C-Y Bonds™ using native amino acids
- Ability to attach multiple therapeutic modalities to a single protein
- Overcomes size and complexity constraints of current conjugation methods
- Improved speed, stability, selectivity, and scalability compared to existing techniques
- Enables the creation of Multi-Payload Conjugates (MPC®)